Publication:
The Clinical Outcome of Hypofractionated Stereotactic Radiotherapy With CyberKnife Robotic Radiosurgery for Perioptic Pituitary Adenoma

dc.contributor.authorPutipun Puataweepongen_US
dc.contributor.authorMantana Dhanachaien_US
dc.contributor.authorAke Hansasutaen_US
dc.contributor.authorSomjai Dangpraserten_US
dc.contributor.authorThiti Swangsilpaen_US
dc.contributor.authorChomporn Sitathaneeen_US
dc.contributor.authorChuleeporn Jiarpinitnunen_US
dc.contributor.authorPatamintita Vitoonpanichen_US
dc.contributor.authorPornpan Yongvithisatiden_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-11T02:05:52Z
dc.date.accessioned2019-03-14T08:03:21Z
dc.date.available2018-12-11T02:05:52Z
dc.date.available2019-03-14T08:03:21Z
dc.date.issued2016-12-01en_US
dc.description.abstract© 2015, © The Author(s) 2015. Stereotactic radiation technique including single fraction radiosurgery and conventional fractionated stereotactic radiotherapy is widely reported as an effective treatment of pituitary adenomas. Because of the restricted radiation tolerance dose of the optic pathway, single fraction radiosurgery has been accepted for small tumor located far away from the optic apparatus, while fractionated stereotactic radiotherapy may be suitable for larger tumor located close to the optic pathway. More recently, hypofractionated stereotactic radiotherapy has become an alternative treatment option that provides high rate of tumor control and visual preservation for the perioptic lesions within 2 to 3 mm of the optic pathway. The objective of the study was to analyze the clinical outcomes of perioptic pituitary adenomas treated with hypofractionated stereotactic radiotherapy. From 2009 to 2012, 40 patients with perioptic pituitary adenoma were treated with CyberKnife robotic radiosurgery. The median tumor volume was 3.35 cm3(range, 0.82-25.86 cm3). The median prescribed dose was 25 Gy (range, 20-28 Gy) in 5 fractions (range, 3-5). After the median follow-up time of 38.5 months (range, 14-71 months), 1 (2.5%) patient with prolactinoma had tumor enlargement, 31 (77.5%) were stable, and the remaining 8 (20%) tumors were smaller in size. No patient’s vision deteriorated after hypofractionated stereotactic radiotherapy. Hormone normalization was observed in 7 (54%) of 13 patients. No newly developed hypopituitarism was detected in our study. These data confirmed that hypofractionated stereotactic radiotherapy achieved high rates of tumor control and visual preservation. Because of the shorter duration of treatment, it may be preferable to use hypofractionated stereotactic radiotherapy over fractionated stereotactic radiotherapy for selected pituitary adenomas immediately adjacent to the optic apparatus.en_US
dc.identifier.citationTechnology in Cancer Research and Treatment. Vol.15, No.6 (2016), NP10-NP15en_US
dc.identifier.doi10.1177/1533034615607113en_US
dc.identifier.issn15330346en_US
dc.identifier.other2-s2.0-84994884825en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/42303
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84994884825&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleThe Clinical Outcome of Hypofractionated Stereotactic Radiotherapy With CyberKnife Robotic Radiosurgery for Perioptic Pituitary Adenomaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84994884825&origin=inwarden_US

Files

Collections